CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
Clinical trial NCT03383965 · UNKNOWN
Trial details
- NCT number
- NCT03383965
- Sponsor
- Immune Cell, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-01
- Primary completion
- 2020-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.